Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07807865) titled 'A Study to Asses Safety and Tolerability of ITI-1284 Given Alone or as an Additional Treatment in Participants With Generalized Anxiety Disorder (GAD)' on Sept. 2.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Intra-Cellular Therapies, Inc.
Condition:
Generalized Anxiety Disorder
Intervention:
Drug: ITI-1284
Recruitment Status: Recruiting
Phase: Phase 3
Date of First Enrollment: September 3, 2026
Target Sample Size: 900
Countries of Recruitment:
United States
To know more,...